Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Kidney Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 8 active trials
17 drugs · 284 active trials
Data updated 20 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tipifarnib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 13, 2020 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2002-06 |
| Capecitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2002-10 |
| Sirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Dec 20, 2005 |
| Busulfan | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 1998-11 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2001-04 |
| Melphalan | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 1998-11 |
| Metformin | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2008-03 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-10 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-01 |
| Peginterferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2002-04 |
| Temozolomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2000-06 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2003-04 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-01 |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-07 |
| Methotrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-10 |
| Panitumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2000-04 |
| Pentostatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2000-09 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | May 1, 2003 |
| Talazoparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | May 20, 2019 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-07 |
| Thiotepa | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1992-10 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2000-01 |
| Azacitidine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-06 |
| Camrelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 23, 2019 |
| Capmatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 24, 2014 |
| Dexamethasone | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-09 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 1, 2015 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-01 |
| Interferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-10 |
| Ixazomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 14, 2015 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 16, 2009 |
| Niraparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 13, 2018 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-01 |
| Pegfilgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 24, 2004 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-03 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1996-01 |
| Vinblastine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1997-05 |
| Vinflunine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-05 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-05 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 19, 2014 |
| Apitolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
| Carfilzomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-10 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-03 |
| Decitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-10 |
| Dostarlimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 7, 2021 |
| Enzastaurin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 30, 2008 |
| Estramustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-07 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.